Abstracts tagged "Disease Activity"

Abstract Number: 0191 • ACR Convergence 2025
Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
Aoibhinn Kelly¹, Maddalena Rupnik², Nasra Ahmed¹, Mrinalini Dey³ and Elena Nikiphorou⁴, ¹King's College Hospital NHS Foundation Trust, London, United Kingdom, ²Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴King's College London, London, United Kingdom
Background/Purpose: Moderate disease in rheumatoid arthritis (RA) is defined as a 28-joint disease activity score (DAS28) of 3.2-5.1(MDAS). As per the National Institute for Health…
Abstract Number: 2430 • ACR Convergence 2025
Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus
Steven Beiser¹, Asma Qureshi¹, Komel Safdar², Zachary Orban¹, Mary Carns², Vanessa Manada De Lobos¹, Cecilia Stumpf³, Mohammad Daud Khan¹, Tyler Therron⁴, Anh Chung¹, Katherine Puev¹, Neil Pillai¹, Kathleen Aren⁵, John F Seagrist², Jing Song⁶, Jason Ross¹, Harris R Perlman², Yvonne Lee², Deborah Rachelle Winter⁷, Borna Bonakdarpour¹, Mariam Siddiqui⁸, Laura Arneson², Rosalind Ramsey-Goldman⁹, Lutfiyya muhammad⁹, Mary Mahieu⁹, Irene Blanco¹⁰, Eric Larson¹, Elena Grebenciucova¹ and Carla Marie Cuda², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL, ³Northwestern University, Elmhurst, IL, ⁴Northwestern Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Worthington, MN, ⁷Northwestern University, Skokie, IL, ⁸Northwestern, Chicago, IL, ⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Northwestern University, Oak Park, IL
Background/Purpose: Mechanisms driving cognitive impairment (CI) in systemic lupus erythematosus (SLE) remain poorly understood; conflicting results exist regarding the relationship between CI and disease activity.…
Abstract Number: 2278 • ACR Convergence 2025
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
John Tesser¹, Angela Crowley², Jane Box³, Joshua June⁴, Pendleton Wickersham⁵, Guillermo Valenzuela⁶, Norman Gaylis⁷, Gordon Lam⁸, Leroy Pacheco⁹, David Ridley¹⁰, Gineth Pinto-Patarroyo¹¹, Stuart Novack¹², Melvin Churchill¹³, Minna Kohler¹⁴, Eric Lee¹⁵, Jose A Pando¹⁶, Glenn R. Parris¹⁷, Jeff Peterson¹⁸, Tina Shah¹⁹, Atul Singhal²⁰, Victoria Vuong²¹, Jeffrey Curtis²² and David Chernoff²³, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ³DJL Clinical Research, PLLC, Charlotte, NC, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁸Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ⁹Albuquerque Ctr for Rheumatology, Albuquerque, NM, ¹⁰Saint Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Herndon, VA, ¹²Nuvance Health network, NORWALK, CT, ¹³Arthritis Center of Nebraska, Lincoln, NE, ¹⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁵Inland Rheumatology and Osteoporosis Medical Group, Upland, CA, ¹⁶Delaware Arthritis, Lewes, DE, ¹⁷PARRIS & ASSOCIATES, Lilburn, GA, ¹⁸Western Washington Arthritis Clinic, Seattle, WA, ¹⁹Kansas City Physician Partners, Kansas City, MO, ²⁰SouthWest Arthritis Research Group, Mesquite, TX, ²¹Long Island Regional Arthritis & Osteoporosis Care, Hicksville, NY, ²²University of Alabama at Birmingham, Birmingham, AL, ²³SetPoint Medical, Sausalito, CA
Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…
Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Christian Pagnoux¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Ulrich Specks⁸, Benjamin Terrier⁹, Lena Börjesson Sjö¹⁰, Priya Jain¹¹, Aadarsh Lal¹², Sofia Necander¹³, Claire Walton¹⁴, Michael Wechsler¹⁵ and Peter Merkel¹⁶, ¹Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹Cochin Hospital, Paris, France, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹²Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹³Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁴Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…
Abstract Number: 1469 • ACR Convergence 2025
Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
Adriana Vázquez-Hernández¹, Emilio Godinez-Lazarini², Erik Cimé-Aké² and Hilda Fragoso-Loyo³, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico
Background/Purpose: In systemic lupus erythematosus (SLE), differences have been observed between patients of different ages at onset. This study evaluates remission, low disease activity, and…
Abstract Number: 1317 • ACR Convergence 2025
The Association Between Insomnia and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 546,822 Patients
Mohamed Abdelsalam¹, Maryam Lasheen², Menat Alla Ayman Ali Mahdy³, Hadeer Hafez⁴, Nourhan Abouelella⁵, Mohamed Al-Adl⁶ and Mohamed Reda Awad⁷, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ³Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Faculty of Medicine, Misr University for Science and Technology, ⁶ october, Al Jizah, Egypt, ⁶Faculty of medicine Al-Azhar University Cairo, Nasr City, Egypt, ⁷Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Insomnia and rheumatoid arthritis (RA) are caught in a snowball effect, where chronic pain disrupts sleep and causes poor sleep quality, which in turn…
Abstract Number: 0580 • ACR Convergence 2025
Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Melissa Eliot², Robert Low³ and Alexis Ogdie⁴, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic disease that causes inflammation of the joints, entheses, spine, skin, and nails.1 While available advanced treatments (txs) for…
Abstract Number: 0500 • ACR Convergence 2025
Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Sama Hajizadeh¹, Tarun Sharma¹, Peri Newman², Julio Hernandez², Rayford June³, Erik Lehman², Nicole Wilson¹, Nancy Olsen⁴ and Sharon Banks⁵, ¹Allegheny Health Network, Pittsburgh, PA, ²Penn State Health/ Penn State College of Medicine, Hershey, PA, ³Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Penn State Milton S. Hershey Medical Center, Hershey, PA
Background/Purpose: In our previous Rheumatoid Arthritis Medication TAPering (RheumTAP) cohort study of patients with stable RA in remission on biologics +/- methotrexate at Allegheny Health…
Abstract Number: 0431 • ACR Convergence 2025
Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
Sangeeta Kumari¹, Eric meldrum¹, Josephine Stein¹, Tirza Bruurmijn¹, Robin de Jong², Katerina Pardali¹, Maarten Kraan¹, Renato Chirivi¹, Rogier Thurlings³ and Michael Nurmohamed², ¹Citryll BV, Oss, Netherlands, ²Reade, Amsterdam, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: Calprotectin is a protein highly expressed in myeloid cells and its elevated presence in blood, and the GI tract is associated with immune mediated…
Abstract Number: 0176 • ACR Convergence 2025
Development and Validation of an Accurate Patient Reported Outcome Measure-based Disease Activity Score to Enable Remote Monitoring in RA
Agnes Looijen¹, Paco Welsing², Sytske Anne Bergstra³, Annette van der Helm-van Mil³ and Pascal de Jong⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands
Background/Purpose: For RA patients, regular monitoring of disease activity is essential, but in-person assessments may not always be feasible due to the increasing pressure on…
Abstract Number: 2423 • ACR Convergence 2025
Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
Michaela Harter¹, Rebecca Hetrick², James Slaven³ and Martha Rodriguez⁴, ¹Indiana University School of Medicine, Indianapolis, IN, ²Indiana University School of Medicine, Zionsville, IN, ³Indiana University School of Medicine, Indianapolis, ⁴Riley Hospital For Children At Indiana University, Carmel, IN
Background/Purpose: Early recognition and treatment of juvenile systemic lupus erythematosus (jSLE) improves outcomes and prevents disease-related mortality. This study examines the contributions of clinical factors…
Abstract Number: 2263 • ACR Convergence 2025
Comparison of a Patient-Reported Disease Activity Measure with Physician-Based Indices in Rheumatoid Arthritis Patients in Nigeria
Uchechukwu Tralagba¹, Courage Uhunmwangho², Olufemi Adelowo³, Henry Nwankwo⁴, Dasetima Altraide¹, Ejiehi Aigbokhan⁵, Ako Itam⁶, Omokhowa Asekhame⁴ and Hakeem Olaosebikan³, ¹University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers, Nigeria, ²Jos University Teaching Hospital, Jos, Plateau, Nigeria, ³Lagos state university teaching hospital, Ikeja, Lagos, Nigeria, ⁴Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra, Nigeria, ⁵University of Benin Teaching Hospital, Benin, Edo, Nigeria, ⁶University of Calabar Teaching Hospital, Calabar, Cross River, Nigeria
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of synovial joints with extra articular manifestations. Disease activity indices in Rheumatoid…
Abstract Number: 1679 • ACR Convergence 2025
Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort
Cécile VAN MULLEM¹, Francesco NATALUCCI¹, Stéphanie DIERCKX¹, Aleksandra AVRAMOVSKA¹, Tatiana SOKOLOVA² and Patrick Durez¹, ¹Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Background/Purpose: The management of Rheumatoid Arthritis (RA) has markedly advanced, enabling the achievement of disease control and remission. Nevertheless, a proportion of patients remains refractory…
Abstract Number: 1435 • ACR Convergence 2025
Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
Denis Poddubnyy¹, Victoria Navarro-Compan², Neil Basu³, Mohammad Naffaa⁴, Tianming Gao⁵, Christopher Saffore⁶, Jamie Urbanik⁷, Bhumik Parikh⁸, Peter Taylor⁹ and Philip J. Mease¹⁰, ¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴The Azriel's Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Rheumatology Unity, Galilee Medical Center, Naharyia, Israel, ⁵AbbVie, North Chicago, IL, ⁶AbbVie Inc., waukegan, IL, ⁷AbbVie, Grayslake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹University of Oxford, Oxford, United Kingdom, ¹⁰Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated improvements in inflammation and nociceptive pain in late phase clinical trials of patients with axSpA.1,2,3 However,…
Abstract Number: 1315 • ACR Convergence 2025
High-resolution thermography and Artificial Intelligence to evaluate and classify Rheumatoid Arthritis
Kale Mayor¹, Joey Mercier¹, Yuxi Long², David Robinson¹, Pingzhao Hu², Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Western University, London, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune polyarthritis that typically affects the small joints of the hands and feet. While imaging modalities such as ultrasound…

« Previous Page
1
…
3
4
5
6
7
…
112
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].